Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529744 | 0.87 | LMNA (0.69) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1865063 | 0.85 | RAB9A (0.75) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1867069 | 0.83 | RAB9A (0.73) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1867467 | 0.81 | MAPT (0.55) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1859778 | 0.80 | RAB9A (0.70) | GAAALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL2523727 | 0.80 | KCNK3 (0.69) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL9046177 | 0.79 | MEN1 (0.59) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL7078864 | 0.78 | MEN1 (0.57) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4638783 | 0.76 | MEN1 (0.73) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1858799 | 0.76 | RAB9A (0.75) | GAAALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478364-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2004-11-24 | — | — | EP | claimed |
| US-20040063765-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-04-01 | — | — | US | claimed |
| WO-2003039549-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2003-05-15 | — | — | WO | claimed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080194588-A1 | Modulation of pathogcnicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194607-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188491-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188535-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1478364-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040063765-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003039549-A2 | SELECTIVE ANTIBACTERIAL AGENTS | 4SC AG (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194588-A1 | Modulation of pathogcnicity | NR4A1, NR4A2, NR3C2 | GAA 4075/4885ALDH1A1 1808/4885MAPT 4719/4885 |
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3227/4885ALDH1A1 3110/4885MAPT 4855/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885 |
| US-20080214635-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | GAA 3223/4885ALDH1A1 3160/4885MAPT 4856/4885 |
| US-20080188491-A1 | Modulation of pathogenicity | NR4A1, MSR1, NR4A2 | GAA 3503/4885ALDH1A1 2806/4885MAPT 4849/4885 |
| US-20080194607-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885 |
| US-20080188535-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885 |
| US-20080188536-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885ALDH1A1 3159/4885MAPT 4855/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3240/4885ALDH1A1 2904/4885MAPT 4857/4885 |
| US-20040063765-A1 | Modulation of pathogenicity | NR1H4, NR4A1, MSR1 | GAA 3255/4885ALDH1A1 2935/4885MAPT 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.